Pharmaceutical composition comprising simvastatin and ezetimibe
The present invention relates to the field of pharmaceutical technology and in particular to novel dosage forms of medicaments containing as active ingredients simvastatin and ezetimibe, or pharmaceutically acceptable salts thereof. The present pharmaceutical compositions are characterized in that the contact of the compositions with oxygen is substantially reduced, such as by coating the composition, providing a medicament useful for the treatment and prevention of atherosclerosis and related conditions, in an environment having an essentially reduced oxygen or humidity, respectively, content.
1. A pharmaceutical composition comprising simvastatin, ezetimibe, and an excipient selected from the group consisting diluents, binding agents, disintegrants, lubricants, sweeteners, glidants, flavourings, colouring agents and combinations thereof, the pharmaceutical composition excluding butylated hydroxyanisole (BHA), 2,6-di-tert-butyl-4-methyl-phenol (BHT), propyl gallate, ascorbic acid, citric acid, edentate disodium and calcium metabisulphite.
2. A pharmaceutical composition according to claim 1 , wherein exposure of the pharmaceutical composition to atmospheric oxygen is reduced such that there is minimal degradation of the simvastatin and ezetimibe.
3. The pharmaceutical composition of claim 1 , wherein exposure of the pharmaceutical composition to oxygen is reduced by means of providing an atmosphere having reduced oxygen content.
4. The pharmaceutical composition of claim 1 , wherein exposure of the pharmaceutical composition to atmospheric oxygen is reduced by means of providing an inert gas atmosphere.
5. The pharmaceutical composition of claim 1 , wherein exposure of the pharmaceutical composition to atmospheric oxygen is reduced by means of absorbents.
6. The pharmaceutical composition of claim 1 , wherein exposure of the pharmaceutical composition to atmospheric oxygen is reduced by means of a coating of the composition.
7. The pharmaceutical composition of claim 6 , wherein the coating is based on carboxymethylcellulose sodium.
8. The pharmaceutical composition of claim 6 , wherein the coating is based on polyvinyl alcohol.
9. The pharmaceutical composition according to claim 1 , which is in a solid dosage form selected from the group consisting of tablets, capsules, sachets, lozenges, powders, pills and granules.
10. The pharmaceutical composition of claim 1 , wherein exposure of the simvastatin and ezetimibe to oxygen is reduced during the preparation of the composition.
11. The pharmaceutical composition of claim 1 , wherein exposure of the simvastatin and ezetimibe to oxygen is reduced during the packaging of the composition.
12. A pharmaceutical composition comprising simvastatin, ezetimibe, and an excipient selected from the group consisting diluents, binding agents, disintegrants, lubricants, sweeteners, glidants, flavourings, colouring agents and combinations thereof, the pharmaceutical composition excluding butylated hydroxyanisole (BHA), 2,6-di-tert-butyl-4-methyl-phenol (BHT), propyl gallate, ascorbic acid, citric acid, edentate disodium and calcium metabisulphite.